accepted manuscript - boris accepted manuscript endophthal… · forms like post-traumatic or...
TRANSCRIPT
source: https://doi.org/10.7892/boris.127193 | downloaded: 11.3.2021
Accepted Manuscript
Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitrealpenetration of systemic antibiotics
Lisa Brockhaus, David Goldblum, Laura Eggenschwiler, Stefan Zimmerli, CatiaMarzolini
PII: S1198-743X(19)30039-4
DOI: https://doi.org/10.1016/j.cmi.2019.01.017
Reference: CMI 1563
To appear in: Clinical Microbiology and Infection
Received Date: 14 December 2018
Accepted Date: 28 January 2019
Please cite this article as: Brockhaus L, Goldblum D, Eggenschwiler L, Zimmerli S, Marzolini C,Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration ofsystemic antibiotics, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2019.01.017.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service toour customers we are providing this early version of the manuscript. The manuscript will undergocopyediting, typesetting, and review of the resulting proof before it is published in its final form. Pleasenote that during the production process errors may be discovered which could affect the content, and alllegal disclaimers that apply to the journal pertain.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal
penetration of systemic antibiotics
Lisa Brockhaus1, David Goldblum2, Laura Eggenschwiler2, Stefan Zimmerli3, Catia Marzolini1 1 Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and
Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.
2 Department of Ophthalmology, University Hospital of Basel and University of Basel,
Switzerland.
3 Department of Infectious Diseases, University Hospital of Bern and University of Bern,
Switzerland
Narrative review
Word count: Abstract: 221
Text: 2497
Tables: 2
Corresponding author:
Lisa Brockhaus, MD
Division of Infectious Diseases
University Hospital Basel
Switzerland
Phone: +41 61 265 50 53
E-mail: [email protected]
Keywords
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Endophthalmitis, systemic antibiotic, vitreous concentration, intravitreal penetration, blood-
retinal barrier
Abstract
Background: Adjunctive systemic antibiotic therapy for treatment of bacterial
endophthalmitis is controversial but common practice due to the severity of the disease. In
absence of guidance documents, several antibiotic regimens are being used without applying
evidence-based prescribing, thus leading to inappropriate treatment of this serious eye
condition.
Objectives: To summarize available data on intravitreal penetration of systemically
administered antibiotics and to discuss their usefulness from a microbiological and
pharmacological point of view.
Sources: We performed a systematic PubMed search of studies investigating antibiotic
concentrations in the vitreous after systemic administration in humans, and selected animal
models.
Content: The best-documented agents achieving therapeutic levels in the vitreous are
meropenem, linezolid and moxifloxacin. Vancomycin, cefazoline, ceftriaxone, ceftazidime,
imipenem and trimethoprim-sulfamethoxazole reach levels justifying their use in specific
situations. Available data do not support the use of ciprofloxacin, levofloxacin,
aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin. With very
limited but available promising data, the use of daptomycin and rifampicin deserves further
investigation.
Implications: The choice of the adjunctive systemic antibiotic agent – in situations where
considered relevant for treatment - must to date be made on an individual base, considering
microbiological aspects as well as operative status and inflammation of the eye. This review
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
gives a systematic overview of antibiotic options and provides guidance to the clinician
striving for optimal systemic antibiotic treatment of bacterial endophthalmitis.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Introduction
Vitrectomy and intravitreal antibiotics are nowadays considered as the gold standard
treatment of bacterial endophthalmitis [1]. Adjunctive use of systemic antibiotics is
controversial but common practice justified by the severity of the disease. Data on intravitreal
antibiotic levels reached by systemic administration are sparse and comprehensive
recommendations for systemic use have not been established [1–3]. The availability of new
antibiotic agents, changing resistance patterns, and new surgical techniques using implants
such as keratoprosthesis justify revisiting their systemic use for endophthalmitis.
This review summarizes available data on intravitreal penetration of systemically
administered antibiotics and discusses preferred regimens for the treatment of bacterial
endophthalmitis from a microbiological and pharmacological perspective.
Definition and commonly isolated microorganisms
Endophthalmitis refers to the inflammation of the internal eye affecting the vitreous cavity
and the anterior chamber, resulting from exogenous (mostly surgery related) or, more rarely
(5-10%) hematogenous insertion of microorganisms [4].
The most commonly isolated microorganisms are coagulase-negative staphylococci (40-
70%), Staphylococcus aureus (10-17%), streptococci (5-15%), other Gram-positive cocci
including enterococci (5%), as well as Gram-negative bacilli (5-10%) including Haemophilus
influenzae and Pseudomonas aeruginosa [5–8]. The microbiologic spectrum of less common
forms like post-traumatic or endogenous endophthalmitis is more varied. For instance,
bacillus sp. is regularly found after open-globe injuries [9]. The bacterial spectrum
encountered may further vary according to local epidemiology and peri-operative
prophylactic regimens [10].
Current treatment recommendations
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
The current mainstays of bacterial endophthalmitis treatment are vitrectomy and intravitreal
antibiotics [1]. Vitrectomy aims to reduce the bacterial load with the intention of a local
“source control”. Although complete vitrectomy would ensure maximal eradication of the
infected tissue, partial vitrectomy is often preferred in clinical practice, because of the lower
associated risk of iatrogenic retinal detachment.
Intravitreal antibiotics are injected immediately after vitrectomy and their administration is
usually repeated after 48 hours if the clinical course is not favourable. The most commonly
used regimens are vancomycin combined with ceftazidime or amikacin. The downside of
repeated injections is an increased risk of retinal toxicity.
Intravitreal dexamethasone is often added to reduce intraocular inflammation despite
conflicting evidence [1]. Corticosteroids accelerate blood-retinal barrier restitution and thus
influence antibiotic penetration.
The role of systemic antibiotics
The single large clinical trial evaluating the role of systemic antibiotics for the treatment of
endophthalmitis is the Endophthalmitis-Vitrectomy-Study conducted in the 1990s [11]. In
this randomized study, no significant difference in visual acuity was found in patients
receiving intravitreal antibiotics followed by intravenous antibiotic therapy compared to
patients receiving only intravitreal treatment. However, this finding has been questioned
because of the exclusion of patients with severe endophthalmitis and the choice of adjunctive
antibiotics: ceftazidime has poor activity against the dominant Gram-positive organisms and
amikacin has very limited intraocular penetration. Since then, only small studies have
evaluated the efficacy of systemic antibiotic therapy in endophthalmitis with varying
methodologies and results [12-13].
Some recommendations advocate the adjunctive use of systemic antibiotics in severe acute
purulent postoperative endophthalmitis [1]. Recommended regimens include vancomycin
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
combined with ceftazidime [14] or imipenem with ciprofloxacin [15]. For the treatment of
endogenous endophthalmitis the use of systemic antibiotics is undisputed [2, 4] .
The pharmacokinetic rationale for adjunctive systemic antibiotics is the rapid elimination of
intravitreally applied antibiotics, with almost complete removal after 24h [16], whereas
systemic administration favors intraocular antibiotic accumulation over time.
Discussing the controversial benefit of adjunctive systemic antibiotics in terms of visual
outcome is beyond the scope of this review. The imminent poor outcome constitutes a strong
argument for clinicians to use systemic therapy. We strongly believe that adjunctive systemic
therapy should not be denied on an individual base, provided that all efforts are made to
isolate the causative pathogen and to apply evidence-based prescribing of antibiotic agents.
Intravitreal penetration of systemic antibiotics
Factors determining the penetration of antibiotics into the eye
The penetration of antibiotics into the posterior segment of the eye after systemic
administration is limited by two blood-retinal barrier mechanisms (BRB): The retinal
pigment endothelial cells located within the retinal cell layers (outer BRB) and the retinal
capillary endothelial cells (inner BRB) [17]. Of note, entry into the anterior segment of the
eye is limited by the blood-aqueous-barrier characterized by less restrictive properties,
thereby resulting in different aqueous and vitreous drug concentrations.
Drug permeability across the blood-retinal barriers depends on drug characteristics such as
the molecular size, lipophilicity, ionization and protein binding. Of interest, BRB was shown
to be more permeable than the blood-brain-barrier (BBB) owing to morphological differences
[17]. As in the BBB, ocular inflammation increases drug permeability across the BRB.
Elimination of antibiotics from the vitreous occurs via two routes: passive diffusion to the
anterior chamber and through the Schlemm’s channel (anterior route), and retrograde
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
transport through the blood-retinal barrier (posterior route). Clearance pathways from the
vitreous depends not only on physico-chemical drug properties and ocular inflammation, but
also on the surgical status [18]. Post-operative aphakia – after removal of an artificial intra-
ocular lens – as well as vitrectomy influence elimination of antibiotics [19].
Pharmacokinetic studies
The knowledge of antibiotics pharmacokinetics in the eye is derived from two types of
studies: single concentration measurements in human eyes performed at the time of surgery,
and rabbit models allowing for repetitive drug measurements. Several limitations should be
considered: although single drug measurements are of high value for antibiotics characterized
by a concentration-dependent killing effect (aminoglycosides, daptomycin), this approach is
less informative for antibiotics with a killing profile that depends on time-above-MIC (beta-
lactams) or AUC/MIC (fluoroquinolones, vancomycin, linezolid).
1) Common pharmacodynamic index values (such as Cmax/MIC used in most of the
assessed studies) do not necessarily reflect efficacy in the complex microenvironment
of the eye.
2) Comprehensive MIC-studies of endophthalmitis isolates are missing. In this review
we use EUCAST breakpoints and wild-type distributions (ECOFF) [20] (table 2) as a
reference to estimate potential efficacies of antibiotics.
3) Animal studies must be interpreted with caution, as they do not fully reflect the
pharmacokinetics in humans.
Suitable publications were identified by a PubMed search using the terms [antibiotic name]
and [vitreous] and [systemic/oral/intravenous]. If no publications were found, the search was
complemented by the terms [eye] and [penetration]. Rabbit model studies were included for
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
antibiotics with limited human data or if they provided additional relevant information.
Studies are summarized in table 1.
Review of available literature
Vancomycin
Vancomycin did not show any accumulation in phakic (including inflamed) eyes in a rabbit
study [21]. Aphakic-vitrectomized eyes showed vitreous levels just above breakpoints of
commonly involved Gram-positive organisms after one dose. In aphakic eyes, comparable
levels were only reached after prolonged therapy. The poor intravitreal penetration of
vancomycin is consistent with the limited CSF penetration [22] and explained by its high
molecular weight and hydrophilicity.
The rationale for its continued empiric use [14] despite limited data, is its microbiological
spectrum covering almost 100% of Gram-positive organisms causing endophthalmitis [7].
Available data nevertheless suggest that systemic administration should only be considered in
aphakic eyes. Given the delay in achieving sufficient concentrations, systemic administration
should follow immediately intravitreal injection of the same agent.
Penicillins
Poor vitreal penetration of ampicillin and amoxicillin were demonstrated in rabbit models
[23-24]. Similarly, insufficient vitreous concentrations of piperacillin were demonstrated in
human eyes with diverse operative status [25]. The vitreal penetration of penicillin G has not
been studied but based on CSF penetration data [22] and drug properties, penetration into the
vitreous is anticipated to be minimal. Nevertheless, in analogy to CSF infections, high
systemic doses might provide effective vitreous levels for streptococcal endophthalmitis.
Available data suggest that systemic administration of most penicillins is not appropriate to
treat endophthalmitis. Penicillin G vitreous levels remain to be investigated.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Cephalosporins
Cefazoline vitreous concentrations are issued from a large rabbit study [26] showing levels
well above streptococcal breakpoints in aphakic-vitrectomized inflamed eyes but
undetectable levels in phakic non-inflamed eyes.
Ceftriaxone was detectable in human phakic non-inflamed eyes after multiple dosing [27] at
levels well above streptococci and enterobacteriaceae breakpoints, but below the ECOFF of
S.aureus. Whether the observed levels result from accumulation after repetitive dosing, or
rapid penetration as previously shown in CSF studies [28], is not known.
Vitreous levels of ceftazidime are based on two rabbit studies [29-30]. Levels were above
enterobacteriaceae breakpoints in aphakic-vitrectomized inflamed eyes. Only delayed
penetration was observed in non-vitrectomized inflamed eyes and undetectable levels were
found in phakic non-inflamed eyes [29].
Cefepime showed low vitreous levels in human phakic non-inflamed eyes [31], nonetheless
penetration in inflamed eyes have not been studied.
In summary, cefazoline, ceftriaxone and ceftazidime can be considered as targeted therapy
when the pathogen is identified and the MIC of the isolate has been determined, yet on a thin
evidence base. Ceftazidime is likely to be effective against most enterobacteriaceae in
aphakic-vitrectomized eyes. Since it exhibits very limited anti-streptococcal and no anti-
staphylococcal activity, it should not be used to cover Gram-positive organisms. Cefepime
cannot be recommended as observed levels are clearly below those of other cephalosporins,
yet investigation in inflamed eyes is warranted. Neither ceftazidime nor cefepime can be
recommended to treat pseudomonas endophthalmitis based on available data.
Carbapenems
Two studies in human phakic non-inflamed eyes showed imipenem vitreous concentrations
around 2.0 ug/ml [32-33]. Meropenem was shown to rapidly achieve four-fold higher
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
vitreous concentrations in a comparable study [34]. This finding is consistent with observed
high meropenem levels in CSF [22] and explained by favorable physicochemical properties.
Unlike imipenem, the observed levels of meropenem clearly exceed breakpoints for relevant
Gram-positive and Gram-negative organisms.
The potential value of carbapenems in empirical treatment – as single agents - is limited by
the high prevalence of oxacillin-resistent coagulase negative staphylococci also in ophthalmic
isolates [8]. For empiric combination therapy, we would advocate the use of meropenem
rather than imipenem based on the above-discussed data. Furthermore, meropenem appears to
be the preferred option for targeted Pseudomonas treatment, particularly when considering
the insufficient concentrations of ciprofloxacin, piperacillin, ceftazidime and cefepime as
discussed above.
Rifampicin
High rifampicin vitreous levels were observed in phakic non-inflamed rabbit eyes [35],
however with doses that, corrected for weight, would largely exceed tolerated doses in
humans.
Human studies are limited to aqueous levels, observed to be 0.2-1.3 ug/ml [36]. As
rifampicin vitreous levels were consistently shown to be half of aqueous levels [31], human
vitreous levels could be expected to exceed 0.1 ug/ml, which is well above breakpoints for
staphylococci.
A role of rifampicin in endophthalmitis after foreign-body implantation, incomplete
vitrectomy, and aggressive S.aureus-infection deserves further consideration due to its
bactericidal and biofilm-active-properties. Importantly, rifampicin has to be combined with
an effective second anti-staphylococcal agent to prevent resistance.
Linezolid
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Mean vitreous levels of linezolid in phakic non-inflamed human eyes range from 1.2 to 3.7
ug/ml after one dose [37–40], with two studies showing further accumulation after two doses
(4.5 and 5.7 ug/ml) [37, 39]. The good penetration into the vitreous is consistent with CSF
penetration [22].
Considering breakpoints of Gram-positive organisms, sufficient vitreous levels are likely to
be attained after two doses. The drug, however, is bacteriostatic.
The well documented ocular penetration and comprehensive coverage of Gram-positive
germs make of linezolid a potential alternative to vancomycin. Caution is needed due to its
toxicity (myelosuppression, peripheral neuropathy, optic neuropathy), although relatively
infrequent in short-term administration [41].
Daptomycin
Knowledge of daptomycin penetration is limited to one case report of a patient treated for
MRSA-endophthalmitis in a strongly inflamed, phakic, non-vitrectomized eye [42]. Single
dose administration (10 mg/kg) resulted in a vitreous concentration of 12.4 ug/ml 42h post
administration (patient had renal insufficiency). This finding appears promising considering
low staphylococcal breakpoints and the drug’s bactericidal properties, but its use remains
experimental to date.
Aminoglycosides
Vitreous concentrations far below breakpoints of relevant pathogens were shown after
intravenous administration of amikacin and gentamycin in a rabbit study [43], despite study
conditions expected to enhance vitreous levels (inflammation, aphakia and vitrectomy).
Given the availability of better alternatives, there is no role for systemic administration of
aminoglycosides in endophthalmitis.
Fluoroquinolones
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Despite relatively good vitreous/serum (V/S) ratios owing to favourable physicochemical
properties, observed concentrations in vitreous proved insufficient for ciprofloxacin [44–50]
and levofloxacin [38, 51-52].
Moxifloxacin demonstrated concentrations well above breakpoints of relevant organisms
after two doses [53-54], whereas concentrations were significantly lower after a single dose
[55-56]. The low concentrations of the Vedantham study can be explained by an inadequate
short sampling time of 90 minutes after oral administration [56] . Moxifloxacin maximal CSF
levels were shown to occur 2-3 hours after maximal systemic levels [57].
In summary, there are sufficient data to oppose the use of ciprofloxacin and levofloxacin for
the treatment of endophthalmitis. Conversely, several studies consistently demonstrating
satisfactory moxifloxacin levels are available. Given the observed higher levels with
moxifloxacin 800mg, this increased dosage can be considered with a careful monitoring for
side effects. Safety data on this dosage are not comprehensive to date [58].
Moxifloxacin lacks activity against most oxacillin-resistant coagulase-negative staphylococci
[8]), and streptococci rapidly develop resistance particularly when drug concentrations are
low. Therefore, the use of moxifloxacin for empirical treatment of endophthalmitis is limited.
Trimethoprim-Sulfamethoxazole
Sulfonamides and trimethoprim have demonstrated a moderate penetration in the vitreous in
one human study [59]. The doses used, however, were below those for the treatment of
meningitis [60]. The observed concentrations are not exceeding breakpoints of all relevant
organisms although higher concentrations might be reached with increased doses.
Concentrations are far below the breakpoint of Stenotrophomonas maltophilia (4 ug/ml)
suggesting difficulty in treating this pathogen.
Due to limited data and better alternatives for Gram-positive organisms, there is no current
role for TMP/SMX in systemic endophthalmitis treatment.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Clarithromycin
Based on one human study of phakic non-inflamed eyes showing insufficient vitreous levels
[61], there is no argument to recommend clarithromycin for endophthalmitis treatment.
Similarly insufficient levels have been reported in CSF, where the use of clarithromycin is
limited to case reports of successful treatment of atypic organisms [22].
Conclusion
Data on the intravitreal concentrations of systemic antibiotics are generally scarce and are
based on a single study for many agents. Relatively good evidence exists for therapeutic
vitreous levels of meropenem, linezolid and high-dose moxifloxacin. None covers the
required bacterial spectrum when used empirically as single agents, but the combination of
linezolid with meropenem in empirical treatment of endophthalmitis may offer broad activity
against the majority of pathogens. Vancomycin, cefazoline, ceftriaxone, ceftazidime,
imipenem, daptomycin and TMP-SMX exhibit levels supporting their use in specific
situations for targeted therapy. The operative status of the infected eye needs also to be
considered. Available data do not support the use of ciprofloxacin, levofloxacin,
aminoglycosides, aminopenicillins, piperacillin, cefepime or clarithromycin. Rifampicin may
be considered for combination therapy in complicated staphylococcal infections. Further data
on daptomycin vitreous penetration would be valuable.
The choice of the adjunctive systemic antibiotic agent – in situations where considered
relevant for treatment - must to date be made on an individual base, taking into account
suspected or detected organisms, operative status, intraocular inflammatory activity and drug
side effect profiles. Future research should assess the clinical outcome after use of systemic
antibiotics with documented good intraocular penetration (e.g. meropenem, linezolid and
moxifloxacin), and assess the role of rifampicin for staphylococcal infections.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Transparency declaration
The authors declare no competing interests regarding this manuscript. This work did not
receive any funding.
Access to data
All studies included in this review are publicly available.
Author contributions
LB has done the literature search, analyzed and compiled the data. DG, LE have provided
input in relation to ophthalmological and ophthalmo-surgical aspects. CM has contributed to
the pharmacological content and analysis of data. SZ has participated in the interpretation of
data and revised the manuscript. LB and CM have drafted the manuscript. All authors have
revised the manuscript for intellectual content and approved the final submitted version.
Acknowledgement
We thank Prof. Manuel Battegay for helpful comments on an earlier draft of this paper.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
References
[1] Barry P, Cordovés L, Gardner S. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions. 2013. http://www.escrs.org/endophthalmitis
[2] Birnbaum F, Gupta G. Endogenous Endophthalmitis: Diagnosis and Treatment. EyeNet Mag 2016;6:33–35.
[3] Wakely L, Sheard R, Hospital RH. Recent advances in Endophthalmitis Management. Focus 2014;2:5-6.
[4] Kernt M, Kampik A. Endophthalmitis : Pathogenesis, clinical presentation, management, and perspectives. Clin Ophthalmol 2010;4:121–135.
[5] Ong A, Te NA, Zagora S, Symes R, Yates W, Chang A et al. Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora. Clin Exp Ophthalmol 2018;jul:1–6. (Epub ahead of print)
[6] Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH et al. Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996;122(1),1–17.
[7] Gentile RC, Shukla S, Shah M, Ritterband DC, Engelbert M, Davis A et al. Microbiological spectrum and antibiotic sensitivity in endophthalmitis: A 25-year review. Ophthalmology 2014;121(8):1634–1642.
[8] Asbell PA, Mah FS, Sanfilippo CM, DeCory HH. Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humor in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. J Cataract Refract Surg 2016;42(12):1841–1843.
[9] Miller JJ, Scott IU, Flynn HW jr, Smiddy WE, Murray TG, Berrocal A et al. Endophthalmitis Caused by Bacillus Species. Am J Ophthalmol 2008;145(5):883–888.
[10] Friling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after catarcat surgery: Swedish national study. J Cataract Refract Surg 2013;39(1):15–21.
[11] Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113(12):1479–1496.
[12] Tappeiner C, Schuerch K, Goldblum D, Zimmerli S, Fleischhauer JC, Frueh BE. Combined meropenem and linezolid as a systemic treatment for postoperative endophthalmitis. Klin Monatsbl Augenheilkd 2010;227(4):257–261.
[13] Hooper CY, Lightman SL, Pacheco P, Tam PMK, Khan A, Taylor SRJ. Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery. Acta Ophthalmol 2012;90(7):572–573.
[14] Behrens-Baumann W. Current Therapy for Postoperative Endophthalmitis. Klin Monatsbl für Augenheilk 2008;225(11):919–923.
[15] German Society for Cataract & Refractive Surgeons. Leitlinie zur Prophylaxe und Therapie von Endophthalmitiden. 2005.
http://www.dgii.org/de/empfehlungen-101.html
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
[16] Ficker L, Meredith T, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest Ophthalmol Vis Sci 1990;31(3):502–505.
[17] Del Amo E, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Progress in Retinal and Eye Research Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res 2017;57:134–185.
[18] Luaces-Rodríguez A, González-Barcia M, Blanco-Teijeiro M, Gil-Martinez M, Gonzalez F, Gomez-Ulla F et al. Review of Introcular Pharmakokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis. Pharmaceutics 2018;10(66);1–15.
[19] Radhika M, Mithal K, Bawdekar A, Dave V, Jindal A, Relhan N, et al. Pharmacokinetics of intravitreal antibiotics in endophthalmitis. J Ophthalmic Inflamm Infect 2014;4(22):1–9.
[20] European Comitee for Suscepitibility Testing.
http://www.eucast.org/clinical_breakpoints. Version 8.1 (accessed in May 2018)
[21] Meredith TA, Aguilar HE, Shaarawy A, Kincaid M, Dick J, Niesman MR. Vancomycin levels in the vitreous cavity after intravenous administration. Am J Ophthalmol 1995;119(6):774–778.
[22] Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23(4):858–883.
[23] Salminen L. Ampicillin penetration into the rabbit eye. Acta Ophthalmol 1878;56: 977–938.
[24] Faigenbaum S, Boyle G, Prywes A, Abel R, Leopold I. Intraocular Penetration of Amoxicillin. Am J Ophthalmol 1976;82(4):598–603.
[25] Robinet A, Le Bot M, Colin J, Riche C. Penetration of Piperacillin into the vitreous after Intravenous Administration. Retina 1998;18(6):526–530.
[26] Martin DF, Ficker LA, Gardner SK, Louis A, Doses RA. Vitreous cefazolin levels after intravenous injection. Arch Ophthalmol 1990;108: 411–414.
[27] Sharir M, Triesrer G, Kneer J, Rubinstein E. The Intravitreal Penetration of Ceftriaxone in Man following Systemic Administration. Invest Ophthalmol Vis Sci 1989;30(10):2179–2183.
[28] Del Rio M, McCracken G, Nelson J, Chrane D, Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother 1982;22(4):622–627.
[29] Aguilar H, Meredith T, Shaarawy A, Kincaid M, Dick J. Vitreous cavity penetration of ceftazidime after intravenous administration. Retina 1995;15:154–159.
[30] Walstad R, Blika S. Penetration of Ceftazidime into the Normal Rabbit and Human Eye. Scand J Infect Dis 1985;44:63–67.
[31] Aras C, Ozdamar A, Ozturk R, Karacorla M, Ozkan S. Intravitreal penetration of cefepime after systemic administration to humans. Ophthalmologica 2002;216:261–264.
[32] Adenis J, Mounier M, Salomon J, Denis F. Human vitreous penetration of imipenem.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
Eur J Ophthalmol 1994;4(2):115–117.
[33] Axelrod J, Newton J, Klein R, Bergen R, Sheikh M. Penetration of Imipenem Into Human Aqueous and Vitreous Humor. Am J Ophthalmol 1987;104:649–653.
[34] Schauersberger J, Amon M, Wedrich A, Nepp J, El Menyawi I, Derbolav A, et al. Penetration and decay of meropenem into the human aqueous humor and vitreous. J Ocul Pharmacol Ther 1999;15(5):439–445.
[35] Wong K, D’Amico D, Oum B, Baker P, Kenyon K. Intraocular penetration of rifampin after oral administration. Graefe’s Arch Exp Ophthalmol 1990;228:40–43.
[36] Outman WR, Levitz RE, Hill DA, Nightingale CH. Intraocular penetration of rifampin in humans. Antimicrob. Agents Chemother 1992;36(7):1575–1576.
[37] Fiscella RG, Lai W, Buerk B, Khan M, Rodvold KA, Pulido JS, et al. Aqueous and vitreous penetration of linezolid after oral administration. Ophthalmology 2004;111(6):1191–1195.
[38] George J, Fiscella R, Blair M, Rodvold K, Ulanski L, Stokes J, et al. Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. J Ocul Pharmacol Ther 2010;26(6):579–586.
[39] Horcajada JP, Atienza R, Sarasa M, Soy D, Adán A, Mensa J. Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration. J Antimicrob Chemother, vol. 63, no. 3, pp. 550–552, 2009.
[40] Ciulla T, Comer G, Peloquin C, Wheeler J. Human vitreous distribution of linezolid after a single oral dose. Retina 2005;25:619–624.
[41] Vazquez J, Arnold AC, Swanson RN, Biswas P, Bassetti M. Safety of long-term use of linezolid : results of an open-label study. Ther Clin Risk Manag 2016;12:1347–1354.
[42] Sheridan K, Potoski B, Shields R, Nau G. Presence of Adequate Intravitreal Concentration of Daptomycin After Systemic Intravenous Administration in an Patient with Endogenous Endophthalmitis. Pharmacotherapy 2010;30:1247–1251.
[43] El-Massry A, Meredith TA, Aguilar HE; Shaarawy A, Kincaid M, Dick J, et al. Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am J Ophthalmol 1996;122(5):684–689.
[44] Morlet N, Graham GG, Gatus B, McLachlan AJ, Salonikas C, Naydoo D, et al. Pharmacokinetics of Ciprofloxacin in the Human Eye: a Clinical Study and Population Pharmacokinetic Analysis. Antimicrob Agents Chemother 2000;44(6):1674–1679.
[45] Cekic O, Batman C, Yasar Ü, Basci N, Bozkurt A, Kayaalp S. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. Eye, 1999;13:555–558.
[46] El Baba F, Trousdale M, Gauderman W, Wagner D, Liggett P. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology 1992;99(4):483–486.
[47] Keren G, Alhalel A, Bartov E, Kitzes-Cohen R, Rubinstein E, Segev S, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991;32(8):2388–2392.
[48] Sweeney G, Fern A, Lindsay G, Doig M. Penetration of ciprofloxacin into the aqueous humour of the uninflamed human eye after oral administration. J Antimicrob Chemother 1990;26(1):99–105.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
[49] Mounier M, Adenis J, Denis F. Intraocular penetration of ciprofloxacin after infusion and oral administration. Pathol Biol 1988;36(5):724–727.
[50] Madu AA, Mayers M, Perkins R, Liu W, Drusano GL, Aswani R, et al. Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 1996;63(2):129–136.
[51] Fiscella R, Nguyen TKP, Cwik MJ, Philpotts BA, Friedlander D. Alter M et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999;106:2286–2290.
[52] Herbert EN, Pearce IA, McGalliard J, Wong D, Groenewald C. Vitreous penetration of levofloxacin in the uninflamed phakic human eye. Br J Ophthalmol 2002;86(4):387–389.
[53] Hariprasad S, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, et al. Vitreous and Aqueous Penetration of Orally Administered Moxifloxacin in Humans. Arch Ophthalmol 2006;124:178–182.
[54] Fuller J, Lott MN, Henson N, Bhatti A, Singh H, McGwin G, et al.Vitreal penetration of oral and topical moxifloxacin in humans. Am J Ophthalmol 2007;143(2):338–340.
[55] Lott MN, Fuller J, Hancock H, Singh J, Singh H, McGwin G, et al.Vitreal penetration of oral moxifloxacin in humans. Retina 2008;28(3):473–476.
[56] Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalaksmi R, Ramasamy K. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Eye 2006;20:1273–1278.
[57] Alffenaar JWC, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, et al. Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis. Clin Infect Dis 2009;49(7):1080–1082.
[58] Ruslami R, Rizal Ganiem A, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13(1):27–35.
[59] Feiz V, Nijm L, Glickman R, Morse L, Telander D, Park S, et al. Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans. Cornea 2013;2(10):1315–1320.
[60] Goodwin C, Bucens M, Davis R, Norcott T. High-dose co-trimoxazole and its penetration through uninflamed meninges. Med J Aust 1981;2(1):24–27.
[61] Al-Sibai MB, Al-Kaff AS, Raines D, El-Yazigi A. Ocular penetration of oral clarithromycin in humans. J Ocul Pharmacol Ther 1998;14(6)575–583.
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
table 1. Studies evaluating vitreous concentrations after systemic administration of antibiotics
antibiotic model operative statusa
inflammation subject dose mean Cmax after 1 dose V/S vitreous antibiotic references
statusb
number (ug/ml) level > MICc
Vancomycin rabbit ph/aph/a-v inf+non-inf 58 15 mg/kg iv 5.4 (a-v inf), 1.1 (aph inf), 0.0 (ph inf) yes in a-v inf Meredith 1994 [21]
Ampicillin rabbit ph non-inf 49 50 mg/kg iv 0.1 no Salminen 1978 [23]
Amoxicillin rabbit ph non-inf 52 50/500 mg/kg iv (!) 0.2/1.6 0.02 Faigenbaum [24]
Piperacillin human ph/ps/aph inf+non-inf 45 4 g iv undetectable no Robinet 1998 [25]
Cefazoline rabbit ph/a-v inf+non-inf 40 50 mg/kg iv 6.7 (a-v inf), 3.0 (ph inf) yes in a-v inf Martin 1990 [26]
Ceftriaxon human ph non-inf 17 2g im bid 5.1 after 6 doses 0.04 partially Sharir 1998 [27]
Ceftazidime rabbit ph/aph/a-v inf+non-inf 46 50 mg/kg iv 35.4 (a-v inf), 0 (aph inf, ph inf) 0.3 partially Aguilar 1995 [29]
Ceftazidime rabbit ph non-inf 15 50 mg/kg iv <1 no Walstad 1985 [30]
Cefepime human ph non-inf 30 1g/2g iv 1.9/2.9 0.08 no Aras 2002 [31]
Imipenem human ph/ps non-inf 10 0.5g/1g iv 0.2/1.1 0.08 partially Adenis 1994 [32]
Imipenem human ph non-inf 10 1g iv 2.5 0.1 partially Axelrod 1987 [33]
Meropenem human ph non-inf 14 2g iv 8.9 0.3 yes Schauersberger 1999 [34]
Rifampicin rabbit ph non-inf ? 150/300/600mg po (!) 2.2/2.6/15.2 yes Wong 1990 [35]
Linezolid human ph non-inf 29 600mg po 2.3 0.3 partially Fiscella 2004 [37]
Linezolid human ph non-inf 16 600mg po 3.7 0.8 yes George 2010 [38]
Linezolid human ph non-inf 24 600mg iv/po 3.7 0.6 yes Horcajada 2008 [39]
Linezolid human ph non-inf 12 600mg po 1.2 0.1 partially Ciulla 2005 [40]
Daptomycin human ph inf 1 10 mg/kg iv 12.4 0.3 yes Sheridan 2010 [42]
Amikacin rabbit a-v inf 7 6 mg/kg iv 8.5 no El-Massry 1996 [43]
Gentamycin rabbit a-v inf 7 1.6 mg/kg iv 1.8 no El-Massry 1996 [43]
Ciprofloxacin human ph non-inf various 0.1-0.5 no Morlet 2000 [44], et al. [45-50]
Levofloxacin human ph non-inf 45 500mg po od/bid 0.6; 2.5 after 2 doses 0.3 no Fiscella 1999 [51]
Levofloxacin human ph non-inf 10 500 mg po 0.8 0.3 no Herbert 2002 [52]
Levofloxacin human ph non-inf 16 750 mg po 2.8 0.5 partially George 2010 [38]
Moxifloxacin human ph non-inf 13 2x400 mg po bid 1.3 after 2 doses 0.4 yes Hariprasad 2006 [53]
Moxifloxacin human ph/ps non-inf 8 2x400 mg po bid 1.5 after 2 doses yes Fuller 2007 [54]
Moxifloxacin human ph/ps non-inf 21 1x400 mg po 0.6 yes Lott 2008 [55]
Moxifloxacin human ph/ps non-inf 27 1x400 mg po 0.1 0.1 no Vedantham 2006 [56]
Trimethoprim human ph non-inf 10 160 mg po bid 1.8 after 3 doses 0.40 partially Feiz 2013 [60]
Sulfamethoxazole human ph non-inf 10 800 mg po bid 5.9 after 3 doses 0.15 Feiz 2013 [60]
Clarithromycin human ph non-inf 21 500 mg po bid 0.3 after 6 doses 0.2 no Al-Sibai 1998 [61]
a) ph= phakic, ps = pseudophakic, aph = aphakic, a-v = aphakic-vitrectomized
b) inf = inflamed, non-inf = non-inflamed
c) refers to MICs of wild-type pathogens covered by the specific antibiotic agent
d) coverage dependent on species (see text for details)
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
(!) exceeding human doses
V/S = vitreous/serum antibiotic concentration ratio
MANUSCRIP
T
ACCEPTED
ACCEPTED MANUSCRIPT
table 2. EUCAST MIC breakpoints (susceptible ≤) of highly prevalent or otherwise significant organisms in bacterial endophthalmitis (ug/ml).
If breakpoints are not defined, ECOFFs (epidemiological cut-off values) are given if reasonable (*).
antibiotic Str. group Str. Str. viridans coagulase-neg. S.aureus Enterococci Haemophilus Entero- Pseudomonas observed maximum
A/B/C/G pneumoniae group staphylococci influenzae bacteriaceae aeruginosa levels (ug/ml)
Vancomycin 2 2 2 4 2 4 NA NA NA 5.4
Benzylpenicillin 0.25 0.06 0.25 [0.125] [0.125] NA NA NA NA
Ampicillin, Amoxicillina)
0.5 0.5a) a)
4 1 [8] NA 0.1 (- 1.6)
Piperacillin-Tazobactama) a) a) b) b) c) c)
8 16 0
Cefazoline 1 a)
NA 0.5b) b)
NA NA NA NA 3.0-6.7
Ceftriaxonea)
0.5 0.5b)
8* NA 0.125 1 NA 5.1
Ceftazidime NA NA NA NA NA NA NA 1 8 0-35.4
Cefepimea)
1 0.5b)
8* NA 0.25 1 8 2.9
Imipenema)
2 2 0.125* 0.125* 4 2 2 4 1.1-2.5
Meropenema)
2 2 0.5* 0.5* NA 2 2 2 8.9
Rifampicin 0.06 NA 0.06 0.06 NA NA NA NA 15.2
Linezolid 2 2 NA 4 4 4 NA NA NA 1.2-3.7
Daptomycin 1 NA NA 1 1 4d)
NA NA NA 12.4
Amikacin NA NA NA 8 8 NA NA 8 8 8.5
Gentamycin NA NA NA 1 1 NA NA 2 4 1.8
Ciprofloxacin NA NA NA 1 1 [4] 0.06 0.25 0.5 0.1-0.5
Levofloxacin 2 2 NA 1 1 [4] 0.06 0.5 [1] 0.6-2.8
Moxifloxacin 0.5 0.5 NA 0.25 0.25 NA 0.125 0.25 NA 0.1-1.5
TMP-SMX 2
1 1 NA 2 2 [0.03] 0.5 2 NA 1.8
Clarithromycin 0.25 0.25 NA 1 1 NA NA NA NA 0.3
a) inferred from benzylpenicillin susceptibility
b) inferred from oxacillin/cefoxitin susceptibility
c) inferred from ampicillin susceptibility
d) CLSI breakpoint1 cefazoline non-species-related breakpoint 1ug/ml
2 breakpoints are expressed as TMP concentration with a 1:19 TMP-SMX ratio
* ECOFF given; no breakpoints defined
[ ] square brackets: unfavourable therapy due to resistance rate and/or insufficient evidence for efficacy
NA not applicable